Physician profile
Yi-Ping Wen
NPI 1093947616
$6,332.66
in general payments reported to CMS, 2019-2025
27 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $486 · 2023: $4,429 · 2024: $572 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Travel and Lodging: $1,360 · Food and Beverage: $1,244 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Travel and Lodging | $1,359.90 |
| Food and Beverage | $1,244.22 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $3,767.33 | 2022-2023 | Adcetris |
| Abbvie INC. | $878.34 | 2021-2025 | |
| Janssen Biotech, INC. | $324.18 | 2021-2025 | Imbruvica, Darzalex, Talvey |
| Celgene Corporation | $157.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $117.68 | 2023-2024 | |
| Amgen INC. | $115.93 | 2021-2023 | Kyprolis, Nplate, Xgeva |
| Daiichi Sankyo INC. | $106.40 | 2023-2025 | Vanflyta |
| Incyte Corporation | $104.33 | 2021-2022 | |
| Genentech USA, INC. | $97.68 | 2023-2025 | Polivy, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $91.64 | 2022-2024 | Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $87.49 | 2021 | |
| Alexion Pharmaceuticals, INC. | $58.10 | 2023-2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $57.98 | 2022-2024 | Prevymis, Dificid |
| Ipsen Biopharmaceuticals, INC | $44.62 | 2025 | Tazverik |
| Servier Pharmaceuticals LLC | $42.99 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.95 | 2025 | Calquence |
| Emd Serono, INC. | $39.79 | 2024 | |
| Genzyme Corporation | $27.15 | 2024 | |
| Sobi, INC | $24.52 | 2022 | |
| Morphosys, US INC. | $23.50 | 2021 | |
| Adc Therapeutics America, INC. | $22.67 | 2025 | |
| Astellas Pharma US INC | $21.28 | 2023 | Xospata |
| Eisai INC. | $18.43 | 2025 | |
| Melinta Therapeutics, LLC | $17.25 | 2024 | Rezzayo |
| Regeneron Healthcare Solutions, INC. | $15.85 | 2024 | Libtayo |
| Lilly USA, LLC | $15.52 | 2025 | Jaypirca |
| Helsinn Therapeutics (U.S.), INC. | $13.73 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi-Ping Wen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.